RA Capital Nexus Fund III, L.P. bought $17.5M of Mineralys Therapeutics (MLYS)

Executed Mar 13 2025, disclosed Mar 17 2025, 4 days later.

Value, as filed

$17.5M

1,296,296 sh × $13.50

Executed

Mar 13 2025

the trade date, as filed

Disclosed

Mar 17 2025

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-2.5%

-6.4% from execution

Over the 21 trading sessions from the disclosed entry session (Mar 17 2025), the stock returned -2.5% (delay-adjusted); from the execution session (Mar 13 2025), -6.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

RP RA Capital Nexus Fund III, L.P. Director profile →

RA Capital Nexus Fund III, L.P. (Director) filed 1 Form 4 report as a reporting entity in the trailing twelve months (0 purchases, 1 sale), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $14.8M of SION (373,610 sh across 8 lots, as filed), executed Oct 24 2025.

The name

MLYS Mineralys Therapeutics, Inc. MLYS · Healthcare · 50 filings in 24 months ticker →

Healthcare · Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→